NCT03595995View on ClinicalTrials.gov

A Phase 2 Trial to Evaluate the Safety and Efficacy of UB-621

PHASE2UnknownINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

June 30, 2024

Study Completion Date

June 30, 2024

Conditions
Genital Herpes
Interventions
BIOLOGICAL

UB-621

Monoclonal antibody by SC injection

OTHER

Placebo

The placebo is a sterile, clear and colorless or slightly yellow liquid, contains the same composition as UB-621 except drug substance. It is given by SC injection.

Sponsors

Lead Sponsor

United BioPharma
All Listed Sponsors
lead

United BioPharma

INDUSTRY

NCT03595995 - A Phase 2 Trial to Evaluate the Safety and Efficacy of UB-621 | Biotech Hunter | Biotech Hunter